C5AR1 and COVID-19: The strong differences between C5a serum levels of COVID‐19 patients with moderate and severe disease (Gao et al., 2020) indicate that longitudinal monitoring of C5a serum levels in patients with moderate disease might help to identify and stratify patients at risk of developing severe lung injury and TMA.